Literature DB >> 10918545

Should all patients with hypertension have echocardiography?

G de Simone1, G Schillaci, V Palmieri, R B Devereux.   

Abstract

The feasibility of echocardiographic determination of left ventricular (LV) mass, as well as the advantages that might be gained in some clinical circumstances and possible indications are examined in the present review, in relation to the recent WHO/ISH. The information obtained with echocardiograms in arterial hypertension is an important contribution to risk stratification on an epidemiological scale. In clinical practice, under the ascertained condition of a good reliability, an echocardiogram should be recommended as part of the initial work up when patients meet criteria for not starting therapy (low or mild risk WHO-ISH) or in all circumstances in which decision-making might be affected by the echocardiographic result. At present, there is not sufficient evidence to extend the indication of echocardiography also to patients for whom antihypertensive management is already necessitated by identification of high or very high risk status.

Entities:  

Mesh:

Year:  2000        PMID: 10918545     DOI: 10.1038/sj.jhh.1001045

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  2 in total

1.  Evaluation of an open access echocardiography service in the Netherlands: a mixed methods study of indications, outcomes, patient management and trends.

Authors:  Leanne M S G van Heur; Leo H B Baur; Marleen Tent; Cara L B Lodewijks-van der Bolt; Marjolijn Streppel; Ron A G Winkens; Henri E J H Stoffers
Journal:  BMC Health Serv Res       Date:  2010-02-10       Impact factor: 2.655

2.  Electrocardiographic criteria of left ventricular hypertrophy in general population.

Authors:  Edoardo Casiglia; Laura Schiavon; Valérie Tikhonoff; Anna Bascelli; Bortolo Martini; Alberto Mazza; Sandro Caffi; Daniele D'Este; Francesco Bagato; Monica Bolzon; Federica Guidotti; Hilda Haxhi Nasto; Mario Saugo; Francesco Guglielmi; Achille C Pessina
Journal:  Eur J Epidemiol       Date:  2008-03-06       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.